"10.1371_journal.pone.0133255","plos one","2015-07-31T00:00:00Z","Thomas Rehle; Leigh Johnson; Timothy Hallett; Mary Mahy; Andrea Kim; Helen Odido; Dorina Onoya; Sean Jooste; Olive Shisana; Adrian Puren; Bharat Parekh; John Stover","Human Sciences Research Council, Cape Town, South Africa; Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom; UNAIDS, Geneva, Switzerland; Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV/AIDS, Atlanta, GA, United States of America; UNAIDS, Pretoria, South Africa; Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; National Institute for Communicable Diseases, Johannesburg, South Africa; Futures Institute, Glastonbury, CT, United States of America","Conceived and designed the experiments: TR LJ TH MM. Performed the experiments: TR LJ TH MM AK JS. Analyzed the data: TR LJ TH MM AK HO DO SJ JS. Contributed reagents/materials/analysis tools: TR LJ TH MM AK JS HO DO SJ OS AP BP. Wrote the paper: TR LJ TH MM AK JS HO DO SJ OS AP BP.","Recombinant protein (rIDRm) and knowhow to develop the LAg-Avidity EIA and related incidence assays have been licensed to multiple commercial partners as per open licensing policy of the U.S. government. These commercial partners currently include 1) Sedia BioSciences, Portland, OR; 2) Maxim Biotech, Rockville, MD; and 3) Beijing KingHawk Pharamceuticals Inc., Beijing, China. As an inventor of the LAg-Avidity EIA, BP receives royalties from licensing of the technologies as per policies of the U.S. government. All other authors have declared that no competing interests exist. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","07","Thomas Rehle","TR",12,FALSE,4,6,9,12,TRUE,TRUE,FALSE,0,NA,FALSE
